The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: Findings in a cohort of HIV-1 seroconverters

Journal of Infectious Diseases

Volumn 191, Issue 8, 2005, Pages 1321-1324

  Rezza, Giovanni ^a   Fiorelli, Valeria ^a   Dorrucci, Maria ^a   Ciccozzi, Massimo ^a   Tripiciano, Antonella ^a   Scoglio, Arianna ^a   Collacchi, Barbara ^a   Ruiz Alvarez, Maria ^a   Giannetto, Concettina ^a   Caputo, Antonella ^c   Tomasoni, Lina ^d   Castelli, Francesco ^d   Sciandra, Mauro ^e   Sinicco, Alessandro ^e   Ensoli, Fabrizio ^b   Buttò, Stefane ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d Clin of Infect and Trop Diseases   (Italy)

^e AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFE CYCLE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SEROCONVERSION; SEXUAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; COHORT STUDIES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV LONG-TERM SURVIVORS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 20144389726     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428909     Document Type: Article

References (15)

1. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229:69-73.
2. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-87.
3. Krone WJ, Debouck C, Epstein LG, Heutink P, Meloen R, Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988; 26:261-70.
4. Re MC, Vignoli M, Furlini G, et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001; 21:81-9.
5. Reiss P, Lange JM, de Ronde A, et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990; 30:163-8.
6. van Baalen CA, Pontesilli O, Huisman RC, et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78:1913-8.
7. Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998; 1:282-92.
8. Richardson MW, Mirchandani J, Duong J, et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 2003; 57:4-14.
9. Cafaro A, Caputo A, Fracasso C, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643-50.
10. Osterhaus AD, van Baalen CA, Gruters RA, et al. Vaccination with Rev and Tat against AIDS. Vaccine 1999; 17:2713-4.
11. Maggiorella MT, Baroncelli S, Michelini Z, et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258-69.
12. Buttò S, Fiorelli V, Tripiciano A, et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 2003; 188:1171-80.
13. Rezza G, Dorrucci M, Pezzotti P, et al. The seroconversion study on the natural history of HIV infection. In: Nicolosi A, ed. HIV epidemiology: models and methods. New York: Raven Press, 1994:279-89.
14. Pezzotti P, Pappagallo M, Phillips AN, et al. Response to highly active antiretroviral therapy according to duration of HIV infection. J Acquir Immune Defic Syndr 2001; 26:473-9.
15. Reiss P, de Ronde A, Dekker J, et al. Seroconversion to HIV-1 rev- and tat-gene-encoded proteins. AIDS 1989; 3:105-6.